Skip to content

Helping patients reclaim a life of possibility

Menu
  • About us
  • Contact us
logo MPE
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month
        • MPE Masterclass
        • Scholarship programme
        • Care Connect Programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month
        • MPE Masterclass
        • Scholarship programme
        • Care Connect Programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
Dominik Candea

DOMINIK CANDEA

Dominik joined MPE as a Medical and Scientific Officer in March 2025.

Dominik holds a Master of Science degree in Biology from the Johannes Gutenberg University Mainz, Germany. During his studies, Dominik gained early experience in the fields of cancer biology, immunology and hematology. He conducted research on Glioblastoma, Acute Myeloid Leukemia and Graves’ disease and worked as a tutor teaching biology and medical students and was also working part-time for MPE. In 2023, Dominik started a Marie Curie Research Fellowship at the University of Turin, Italy, where he worked on Anaplastic Large Cell Lymphoma, a rare type of Non-Hodgkin Lymphoma. His passion for science and education led him to rejoin MPE as a Medical and Science Officer in spring 2025. Dominik is fluent in Romanian, German, English and Italian. He is currently based in Germany.

 

Recent Posts

Screenshot 2026 10 02 112724

MPE members drive myeloma awareness across Europe during EMD and BCAM

6 October 2026

September proved to be an extraordinary month for myeloma advocacy across MPE’s member network. Our members delivered bold, impactful campaigns to raise awareness during Blood Cancer Awareness Month (BCAM) and…

Read more
CAR-T webinar graphic

MPE webinar: Long-term outcomes of CAR T-cell therapy in myeloma

1 October 2026

Chimeric antigen receptor (CAR) T-cell therapy is a treatment that uses genetically modified immune cells (T-cells) to treat myeloma. While clinical studies have demonstrated the strong efficacy of CAR T-cell…

Read more

MPE strengthens patient voice in cancer quality-of-life research at EORTC meeting

1 October 2026

Last week MPE was in Zagreb for the Autumn EORTC Quality of Life Group meeting, connecting with colleagues working to strengthen the role of quality-of-life data in cancer research. The…

Read more
MPE team at IMS

Highlights from the International Myeloma Society (IMS) annual meeting

30 September 2026

From September 23-26, Myeloma Patients Europe (MPE) attended the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, Scotland. The IMS Annual Meeting is one of the most important international…

Read more
EMAs CHMP positive opinion image

EMA committee recommends melflufen label expansion to third-line myeloma treatment

22 September 2026

On September 17, 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of melphalan flufenamide (melflufen, Pepaxti®) to third-line myeloma…

Read more
Faith Davies

Dr. Faith Davies interview on IMS 2026

17 September 2026

As the International Myeloma Society (IMS) Annual Meeting is taking place this week, we caught up with myeloma expert Dr. Faith Davies, from NYU Langone, about her expectations for the…

Read more
mpe logo negativo 300x249 1

Myeloma Patients Europe AISBL

Avenue Louise 143/4, 1050
Brussels Belgium
© Myeloma Patients Europe 2026
  • Contact
  • About us
  • Privacy policy
  • Terms and conditions
  • Cookies Policy
Go to Top
logo MPE
  • About MPE
    • Our members
    • Our board and staff
    • Medical Advisory Committee
    • Our Strategic Goals
    • Our funding
    • Get involved in MPE activities
    • Become a member
  • Contact us
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
    • Member and patient community programmes
      • Myeloma Awareness Month
      • MPE Masterclass
      • Scholarship programme
      • Care Connect Programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • News
  • European Myeloma Day

PopUp

  • This field is for validation purposes and should be left unchanged.